MNPR Share Price | Monopar Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Monopar Therapeutics, Inc.?

Market Cap: As of Jun 18, Monopar Therapeutics, Inc. has a market capitalization of 208.53 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Monopar Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -16.57 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 55.04 million and total assets of 60.29 million.

Q: What does Monopar Therapeutics, Inc. do?

Overview:Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics for cancer patients, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot:Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market cap: USD 208.53 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.02 Return on Equity: -30.92% Price to Book: 3.89Contact Details:Address: 1000 Skokie Blvd Ste 350, WILMETTE IL: 60091-1146 Tel: 1 847 3880349 Fax: 1 302 6555049 Website: https://www.monopartx.com/

Q: Is Monopar Therapeutics, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Monopar Therapeutics, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish, with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate bullish conditions for both periods. Daily moving averages are bullish, while the KST shows bullish signals on both weekly and monthly charts. However, the Dow Theory indicates a mildly bullish stance on both time frames, and the OBV is mildly bullish weekly but mildly bearish monthly. Overall, the bullish indicators outweigh the bearish ones. There is no available multi-period return data for comparison with the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

287.49 k

Shareholding (Sep 2025)

FII

1.01%

Held by 15 FIIs

DII

90.93%

Held by 8 DIIs

Promoter

0.57%

How big is Monopar Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Monopar Therapeutics, Inc. has a market capitalization of 208.53 million, with net sales of 0.00 million and a net profit of -16.57 million over the latest four quarters. The company reported shareholder's funds of 55.04 million and total assets of 60.29 million as of Dec 24.

View full answer

What does Monopar Therapeutics, Inc. do?

22-Jun-2025

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing cancer therapeutics, with a market cap of approximately $208.53 million and a recent net profit of -$3 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.

View full answer

Is Monopar Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Monopar Therapeutics, Inc. shows a bullish technical trend, supported by strong indicators like MACD and Bollinger Bands, despite some mixed signals from Dow Theory and OBV.

View full answer

Compare Monopar Therapeutics, Inc. with Similar Stocks

Atreca, Inc.CohBar, Inc.Brainstorm Cell Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 470 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-13.73%

Price to Book

3.32

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-31.23%

6 Months

36.24%

1 Year

18.5%

2 Years

3025.27%

3 Years

1553.49%

4 Years

312.17%

5 Years

42.2%

Monopar Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-216.79%

EBIT to Interest (avg)

-10.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

56.08%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.23

EV to EBIT

-9.76

EV to EBITDA

-9.76

EV to Capital Employed

-172.38

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-30.92%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 12 Schemes (7.5%)

Foreign Institutions

Held by 15 Foreign Institutions (1.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -47.06% vs 22.73% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.20",
          "val2": "-1.80",
          "chgp": "-77.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-1.70",
          "chgp": "-47.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -85.71% vs 20.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.20",
          "val2": "-8.80",
          "chgp": "-84.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.60",
          "val2": "-8.40",
          "chgp": "-85.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.20

-1.80

-77.78%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.50

-1.70

-47.06%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -47.06% vs 22.73% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-16.20

-8.80

-84.09%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-15.60

-8.40

-85.71%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -85.71% vs 20.00% in Dec 2023

All Annual Results

Company CV

About Monopar Therapeutics, Inc.

Monopar Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Monopar Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for cancer patients. Its pipeline includes Validive, Camsirubicin and MNPR-101. Validive is a clonidine mucobuccal tablet (clonidine MBT). Validive is designed to be used prophylactically to reduce the incidence, delay the time to onset, and decrease the duration of severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. Its second product candidate, Camsirubicin, is a novel analog of doxorubicin. Camsirubicin is designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining anti-cancer activity. MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. It is developing MNPR-101 for the treatment of advanced cancers.

Company Coordinates

Company Details

1000 Skokie Blvd Ste 350 , WILMETTE IL : 60091-1146

Tel: 1 847 3880349

https://www.monopartx.com/

Registrar Details

Monopar Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Monopar Therapeutics, Inc.?

Watch in Real-Time

What does Monopar Therapeutics, Inc. do?

Is Monopar Therapeutics, Inc. technically bullish or bearish?

Compare Monopar Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Monopar Therapeutics, Inc.

Company Coordinates